| scholarly article | Q13442814 |
| P356 | DOI | 10.1586/17474086.2016.1140034 |
| P8608 | Fatcat ID | release_oqjrdirzzfckpc2orfm4mdjon4 |
| P698 | PubMed publication ID | 26789237 |
| P50 | author | Vittorio Pengo | Q42778559 |
| Maria Orietta Borghi | Q47504194 | ||
| Elena Raschi | Q91206963 | ||
| Cecilia Beatrice Chighizola | Q38544863 | ||
| Pier Luigi Meroni | Q38544871 | ||
| P2093 | author name string | Alessandra Banzato | |
| P2860 | cites work | Increased mortality in patients with the lupus anticoagulant: the Vienna Lupus Anticoagulant and Thrombosis Study (LATS). | Q41157732 |
| Incidence of a first thromboembolic event in carriers of isolated lupus anticoagulant | Q41747738 | ||
| Complexes of anti-prothrombin antibodies and prothrombin cause lupus anticoagulant activity by competing with the binding of clotting factors for catalytic phospholipid surfaces | Q43622736 | ||
| Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. | Q43626449 | ||
| Anti-phosphatidylserine/prothrombin antibodies: an additional diagnostic marker for APS? | Q43878816 | ||
| The effects of phosphatidylserine-dependent antiprothrombin antibody on thrombin generation | Q44449495 | ||
| A simple method to discriminate between beta2-glycoprotein I- and prothrombin-dependent lupus anticoagulants | Q44518849 | ||
| beta2-glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome | Q45021710 | ||
| IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis | Q45126748 | ||
| Confirmation of initial antiphospholipid antibody positivity depends on the antiphospholipid antibody profile. | Q45383876 | ||
| Screening for lupus anticoagulants in patients treated with vitamin K antagonists | Q45878162 | ||
| Patient-derived monoclonal antibodies directed towards beta2 glycoprotein-1 display lupus anticoagulant activity | Q46373484 | ||
| Clinical characterization of antiphospholipid syndrome by detection of IgG antibodies against β2 -glycoprotein i domain 1 and domain 4/5: ratio of anti-domain 1 to anti-domain 4/5 as a useful new biomarker for antiphospholipid syndrome | Q46483595 | ||
| A two-step coagulation test to identify antibeta-glycoprotein I lupus anticoagulants | Q47730463 | ||
| The paradox of the lupus anticoagulant: history and perspectives. | Q48060132 | ||
| Mixing studies in lupus anticoagulant testing are required at least in some type of samples | Q49136219 | ||
| APTT reagent with ellagic acid as activator shows adequate lupus anticoagulant sensitivity in comparison to silica-based reagent. | Q51331039 | ||
| Optimisation of lupus anticoagulant tests: should test samples always be mixed with normal plasma? | Q53087271 | ||
| Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. | Q53190445 | ||
| Interactions between rivaroxaban and antiphospholipid antibodies in thrombotic antiphospholipid syndrome. | Q53551807 | ||
| Anti-beta2-glycoprotein I (beta2GPI) monoclonal antibodies with lupus anticoagulant-like activity enhance the beta2GPI binding to phospholipids | Q24561680 | ||
| Heterogeneity of Russell's viper venom affects the sensitivity of the dilute Russell's viper venom time to lupus anticoagulants | Q28254327 | ||
| International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) | Q28292418 | ||
| Acquired immune-mediated thrombophilia in lymphoproliferative disorders | Q33396280 | ||
| Immunological and molecular analysis of three monoclonal lupus anticoagulant antibodies from a patient with systemic lupus erythematosus | Q33501756 | ||
| Conceptions and misconceptions in testing for lupus anticoagulants | Q34021264 | ||
| Silica clotting time (SCT) as a screening and confirmatory test for detection of the lupus anticoagulants | Q34238136 | ||
| Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature | Q34977289 | ||
| A non-complement-fixing antibody to β2 glycoprotein I as a novel therapy for antiphospholipid syndrome. | Q35124036 | ||
| Treatment of Thrombotic Antiphospholipid Syndrome: The Rationale of Current Management-An Insight into Future Approaches | Q35621012 | ||
| The effect of phospholipids on the formation of immune complexes between autoantibodies and beta2-glycoprotein I or prothrombin | Q35829190 | ||
| Antiphospholipid syndrome associated with infections: clinical and microbiological characteristics | Q36329966 | ||
| The association between antiphospholipid antibodies and placenta mediated complications: a systematic review and meta-analysis | Q37855094 | ||
| Guidelines on the investigation and management of antiphospholipid syndrome | Q37982121 | ||
| Laboratory identification of lupus anticoagulants | Q38008970 | ||
| Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature | Q38122121 | ||
| New tests to detect antiphospholipid antibodies: anti-domain I beta-2-glycoprotein-I antibodies | Q38175886 | ||
| Risk of venous and arterial thrombosis according to type of antiphospholipid antibodies in adults without systemic lupus erythematosus: a systematic review and meta-analysis | Q38177962 | ||
| Antiphospholipid antibody testing and standardization | Q38205953 | ||
| Commonalities and contrasts in recent guidelines for lupus anticoagulant detection | Q38205954 | ||
| 14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends | Q38211487 | ||
| The association between antiphospholipid antibodies and pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature. | Q38362118 | ||
| Clinical course of high-risk patients diagnosed with antiphospholipid syndrome | Q39934417 | ||
| P433 | issue | 4 | |
| P921 | main subject | anticoagulation | Q63279445 |
| P304 | page(s) | 389-400 | |
| P577 | publication date | 2016-01-20 | |
| P1433 | published in | Expert Review of Hematology | Q15734429 |
| P1476 | title | The challenges of lupus anticoagulants | |
| P478 | volume | 9 |
| Q64075728 | Cryptic conspirators: a conversation about thrombocytopenia and antiphospholipid syndrome |
| Q33562780 | Early prediction of postoperative liver dysfunction and clinical outcome using antithrombin III-activity |
| Q92369603 | Interleukin-17/Interleukin-21 and Interferon-γ producing T cells specific for β2 Glycoprotein I in atherosclerosis inflammation of systemic lupus erythematosus patients with antiphospholipid syndrome |
| Q50620167 | Newly developed dilute Russell's viper venom reagents for lupus anticoagulant detection with improved specificity. |
| Q55407136 | Pathogenic Role of Complement in Antiphospholipid Syndrome and Therapeutic Implications. |
| Q39318344 | The Effects of Indirect- and Direct-Acting Anticoagulants on Lupus Anticoagulant Assays: A Large, Retrospective Study at a Coagulation Reference Laboratory. |
| Q48243949 | β2 Glycoprotein I Recognition Drives Th1 Inflammation in Atherosclerotic Plaques of Patients with Primary Antiphospholipid Syndrome |
Search more.